Effect of farmorubicin both free and associated with poly(butylcyanoacrylate) nanoparticles on phagocytic and NK activity of peritoneal exudate cells from tumor-bearing mice

References

• Aquali N, Morjani H, Trussardi A, Soma E, Giroux B, Manfait M. Enhanced cytotoxicity and nuclear accumulation of doxorubicin-loaded nanospheres in human breast cancer MCF7 cells expressing MRP1. Int J Oncol 2003; 23: 1195–1201
   PubMed Web of Science ®Google Scholar
• Ehrke MJ. Immunomodulation in cancer therapeutics. Int Immunopharmacol 2003; 3: 1105–1119
   PubMed Web of Science ®Google Scholar
• Ehrke MJ, Cohen SA, Mihich E. Selective effects of adriamycin on murine host defense systems. Immunol Rev 1982; 65: 594–616
   Google Scholar
• Evans R. Macrophages and neoplasms: New insights and their applications in tumour biology. Cancer Metastasis Rev 1984; 1: 227–239
   Google Scholar
• Fernandez-Urrusuno R, Fattal E, Rodrigues JM, Jr., Féger J, Bedossa P, Couvreur P. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J Biomed Mater Res 1996; 31: 401–408
   PubMed Web of Science ®Google Scholar
• Gaspar R, Preat V, Opperdoes FR, Roland M. Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: Activity against intracellular Leishmania donovani associated with hydrogen peroxide production. Pharm Res 1992; 9: 782–787
   PubMed Web of Science ®Google Scholar
• Kattan J, Droz J-P, Couvreur P, Marino J-P, Boutan-Laroze A, Rougier Ph, Brault Ph, Vranckx H, Grognet J-M, Morge X, Sancho-Garnier H. Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest New Drugs 1992; 10: 191–199
   PubMed Web of Science ®Google Scholar
• Mace K, Mayhew E, Mihich E, Ehrke MJ. Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin. Cancer Res 1988; 48: 130–136
   PubMed Web of Science ®Google Scholar
• Maincent P, Thouvenot P, Amicabile C, Hoffman M, Kreuter J, Couvreur P, Devissaguet JP. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. Pharm Res 1992; 9: 1534–1539
   PubMed Web of Science ®Google Scholar
• Mantovani A. The interaction of cancer chemotherapy agents with mononuclear phagocytes. Adv Pharmacol Chemother 1982; 19: 35–66
   PubMedGoogle Scholar
• Mantovani A, Polentarutti N, Luini W, Peri G, Spreafico F. Role of host defense mechanisms in the antitumor activity of adriamycin and daunomycin in mice. J Natl Cancer Inst 1979; 63: 61–66
   PubMed Web of Science ®Google Scholar
• Martin F, Caignard A, Olsson O, Jeannin JF, Leclerc A. Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro. Cancer Res 1982; 43: 3851–3857
   Google Scholar
• Melichar B, Freedman RS. Immunology of the peritoneal cavity: Relevance for host-tumor relation. Int J Gynecol Cancer 2002; 12: 3–17
   PubMed Web of Science ®Google Scholar
• Mihich E. Historical overview of biologic response modifiers. Cancer Invest 2000; 18: 456–466
   PubMed Web of Science ®Google Scholar
• Mihich E, Ehrke MJ. Anticancer drugs plus cytokines: Immunodulation based therapies of mouse tumors. Int J Immunopharmacol 2000; 22: 1077–1081
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185–229
   PubMed Web of Science ®Google Scholar
• Monneret C. Antitumour anthracyclines. The past, present, future. Actualités de chimie thérapeutique-26^e serie, Societe de chimie therapeutique. Elsevier, Para Universitaire, Amsterdam 2000; 103–130
   Google Scholar
• Poupaert JH, Couvreur P. A computationally derived structural model of doxorubicin interacting with oligomeric polyalkylcyanoacrylate in nanoparticles. J Control Release 2003; 92: 19–26
   PubMed Web of Science ®Google Scholar
• Rudt S, Müller RH. In vitro phagocytosis assay of nano- and microprticles by chemiluminiscence. I. Effect of analytical parameters, particle size and particle concentration. J Control Release 1992; 22: 263–272
   Web of Science ®Google Scholar
• Rykova MP, Spirande IV, Zedgenidze MS, Lyakhov W, Fuks BB. New high sensitive technique for testing natural killers. Immunologiya 1981; 3: 88–90, (in Russian)
   Google Scholar
• Salazar D, Cohen SA. Multiple tumoricidal effector mechanisms induced by adriamycin. Cancer Res 1984; 44: 2561–2566
   PubMed Web of Science ®Google Scholar
• Santoni A, Riccardi C, Sorci V, Herberman RB. Effects of adriamycin on the activity of mouse natural killer cells. J Immunol 1980; 124: 2329–2335
   PubMed Web of Science ®Google Scholar
• Schmidl D. Monocyte/macrophage system and malignancies. Med Pediatr Oncol 1994; 23: 444–449
   PubMedGoogle Scholar
• Schäfer V, von Briezen H, Andreesen R, Steffan A, Royer C, Tröster S, Kreuter J, Rübsamen-Waigmann H. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: A possibility for antiviral drug targeting. Pharm Res 1992; 9: 541–546
   PubMed Web of Science ®Google Scholar
• Simeonova M, Ilarionova M, Konstantinov Chr, Todorov D. Poly(alkylcyanoacrylate) nanoparticles as drug carriers. Investigation of their acute toxicity. Problems Pharmacol Pharm 1987; 1: 68–73, (in Bulgarian)
   Google Scholar
• Simeonova M, Antcheva M, Chorbadjiev K. Study on the effect of poly(butyl-2-cyanoacrylate) nanoparticles and their metabolites on the phagocytic activity of peritoneal exudate cells of mice. Biomaterials 2003; 24: 313–320
   PubMed Web of Science ®Google Scholar
• Simeonova M, Antcheva M, Velichkova R. Poly(butylcyanoacrylate) nanoparticles as potential drug carriers. NATO Science Series, II. Mathematics, physics and chemistry-vol. 180: Advanced biomaterials for biomedical applications, DW Thomas. Kluwer Academic Publishers, The Nederlands 2004; 21–24
   Google Scholar
• Soma CE, Dubernet C, Barratt G, Némati F, Appel M, Benita S, Couvreur P. Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res 1999; 16: 1710–1716
   PubMed Web of Science ®Google Scholar
• Soma CE, Dubernet C, Bentolia D, Benita S, Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000a; 21: 1–7
   PubMed Web of Science ®Google Scholar
• Soma CE, Dubernet C, Barratt G, Benita S, Couvreur P. Investigation of the role of macrophages on the cytotoxicity of doxorubicin-loaded nanoparticles on M5076 cells in vitro. J Control Release 2000b; 68: 283–289
   PubMed Web of Science ®Google Scholar
• Storm G, Steerenberg PA, Emmen F, van Borssum Waalkes M, Crommelin DJA. Release of doxorubicin from peritoneal macrophages exposed in vivo to doxorubicin-containing liposomes. Biochim Biophys Acta 1988; 965: 136–145
   PubMed Web of Science ®Google Scholar
• Ujhazy P, Zaleskis G, Mihich E, Ehrke MJ, Berleth ES. Doxorubicin induces specific immune functions and cytokine expression in peritoneal cells. Cancer Immunol Immunother 2003; 52: 463–472
   PubMed Web of Science ®Google Scholar
• Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: The potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release 2003; 93: 151–160
   PubMed Web of Science ®Google Scholar
• Weiss RB. The anthracyclines: Will we ever find a better doxorubicin?. Semin Oncol 1992; 19: 670–686
   PubMed Web of Science ®Google Scholar